Navigation Links
Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus' Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
Date:8/15/2011

SAN DIEGO and FRANKLIN LAKES, N.J., Aug. 15, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostics company that is part of Nestle Health Science, and the Medco Research Institute®, LLC, a wholly-owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), today announced that they have entered into a collaboration to evaluate the use of Prometheus' Thiopurine Metabolite (PTM) testing for optimizing dosing of 6 mercaptopurine (6MP) or azathioprine (Aza) in patients with inflammatory bowel disease (IBD). Optimization of dosing could lead to improved drug response and delay progression to more aggressive therapy.

(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO)

Thiopurine immunomodulators, such as 6MP or its pro-drug Aza, are effective medical treatments for IBD when appropriately dosed. However, studies have shown that patients are frequently under dosed which can decrease the efficacy of these drugs. Through PTM testing, doctors may be able to select those patients who would benefit from dose adjustments and those that may have a risk of toxicity.  Patients who are not responding due to lack of compliance could also be identified. This collaboration will evaluate whether PTM testing, used early after the decision is made to prescribe thiopurines, increases the time that patients remain on these drugs and thus reduces the rate at which patients transition to expensive alternative treatments.  

"We believe that this collaboration provides an opportunity to show how our Prometheus Thiopurine Metabolite test can be used to optimize immunomodulator therapy for IBD patients," said Joseph Limber, Prometheus's Chief Executive Officer.  "The results of this pilot project could help provide evidence supporting the clinical value and cost effectiveness of the routine use of this testing in patients tak
'/>"/>

SOURCE Medco
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
8. Prometheus Highlights Record Performance in 2010
9. Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
10. Prometheus Announces Agreement to be Acquired by Nestle Health Science
11. Medco Announces Date for Third-Quarter 2009 Financial Results; Company to Provide 2010 Earnings Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a ... diseases and cholesterol gallstones, announced today that the ... approved its request for Fast Track Designation of ... Non-Alcoholic Steato-Hepatitis, or NASH.  FDA ...
(Date:9/23/2014)... 2014  MEDIMETRIKS PHARMACEUTICALS today announced that ... have been elected to Medimetriks, Board of Directors ... who will serve on Medimetriks, Audit Committee, brings ... the Company.  Mr. Lary is currently Managing Director, ... institutional investment firm.  Mr. Lary is responsible for ...
(Date:9/23/2014)... 23, 2014  Vesselon, Inc. today announced the appointment ... effective September 15, 2014. Dr. Raths, appointment follows Vesselon,s ... agent to market a private preferred Series A round ... treatment. "Jurgen,s deep experience across multiple functional ... asset to Vesselon as we develop our device that ...
Breaking Medicine Technology:Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 2Galmed Pharmaceuticals Announces U.S. FDA Approval of Fast Track Designation of Aramchol for the Treatment of NASH 3Medimetriks Pharmaceuticals, Inc. Welcomes Independent Directors Andrew Lary and William Resnick to its Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3
(Date:9/23/2014)... 2014 SOURCE: Solutions from Our ... were made to Rimidi Diabetes and ... with business solutions to challenges faced by patients and ... collaboration between The Hitachi Foundation, Village ... entrepreneurs with the investment capital, mentoring, and support needed ...
(Date:9/23/2014)... Risperdal lawsuits ( http://www.drugbot.com/risperdal/lawsuit/ ) continue ... Liebhard LLP reports. According to an Order issued in ... 19th, the Court has dismissed fraud and negligence per ... on behalf of a man who allegedly developed gynecomastia ... use of Risperdal. In dismissing the Plaintiff’s negligence per ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- The ... million in additional funding in scientific trials to ... and clinical studies. The supplemental monies were ... fields, including basic immunology, cardiovascular physiology, neural circuitry, ... Sept. 23. "This funding strategy demonstrates our ...
(Date:9/23/2014)... They are common suggestions to remedy stress: You just ... out and see people. , Turns out all ... a lot better a new large scale study ... depression, less perceived stress and enhanced mental health and well-being, ... with partners from De Montfort University, James Hutton Institute, and ...
(Date:9/23/2014)... that you may want to get screened and treated ... knife. According to a first-of-its-kind study in the ... journal of the American Society of Anesthesiologists (ASA), patients ... condition prior to surgery are less likely to develop ... , "OSA is a common disorder that affects millions ...
Breaking Medicine News(10 mins):Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuit News: Fraud, Negligence Per Se Claims Dismissed from Florida Complaint, Bernstein Liebhard LLP Reports 3Health News:NIH Adds $10M to Encourage Gender Balance in Clinical Trials 2Health News:Beating stress outdoors? Nature group walks may improve mental health 2Health News:New research suggests sleep apnea screening before surgery 2
... their families to take the following steps:, , ... When you are sick, keep your distance from others to protect them from ... you are sick to help prevent others from catching your illness. Cover your ... and nose with a tissue when coughing or sneezing. It may prevent those ...
... The following is a joint statement from Bruce Yarwood, ... and National Center for Assisted Living (AHCA/NCAL), and Alan ... Home Care: We commend Senators Baucus and Grassley for ... health care policy reforms that will impact every American ...
... April 29 Pennsylvania,s chief agriculture and ... improve national and state food safety initiatives at the ... in Harrisburg. Agriculture Secretary Dennis Wolff and Health Secretary ... in protecting the food supply and responding to outbreaks, ...
... Almost half of those in ICU had deficient levels, study ... levels are deficient in many critically ill patients, new research ... almost half of people in an intensive care unit were ... to be common in seriously ill patients," said study author ...
... PALO ALTO, Calif., April 29 Varian Medical Systems ... from continuing operations of $0.64 per diluted share in ... earnings from continuing operations of $0.57 per diluted share ... research instruments operation, net earnings per diluted share in ...
... Sangamo BioSciences, Inc. (Nasdaq: SGMO ) today ... first quarter ended March 31, 2009, Sangamo reported a consolidated ... to a net loss of $8.0 million, or $0.20 per ... 31, 2009, the company had cash and cash equivalents, marketable ...
Cached Medicine News:Health News:Workforce Swine Flu Pandemic Survival Preparedness Tips For Business 2Health News:National Long Term Care Leaders Praise Overall Baucus Health Reform Effort, Express Specific Concerns Moving Forward 2Health News:Pennsylvania Governor's Food Safety Council Meets to Discuss Food Supply Protection 2Health News:Critically Ill Patients Lack Vitamin D 2Health News:Critically Ill Patients Lack Vitamin D 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 2Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 3Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 4Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 5Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 6Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 7Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 8Health News:Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2009 9Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 2Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 3Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 4Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 5Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 6Health News:Sangamo BioSciences Reports First Quarter 2009 Financial Results 7
Bone Curette, 145 mm...
Kevorkian Collector Endocervical Curette is a stainless-steel curette with rounded tip....
Cobb Curettes, 11 inches...
...
Medicine Products: